AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+11.84%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.89B
AUM Growth
+$3.89B
(+0.38%)
Cap. Flow
-$658M
Cap. Flow
% of AUM
-16.88%
Top 10 Holdings %
Top 10 Hldgs %
78.03%
Holding
129
New
21
Increased
28
Reduced
28
Closed
19
Top Buys
| 1 |
Lexicon Pharmaceuticals
LXRX
|
$96.7M |
| 2 |
Avidity Biosciences
RNA
|
$26.8M |
| 3 |
Cullinan Oncology
CGEM
|
$18.5M |
| 4 |
Merus
MRUS
|
$18.1M |
| 5 |
Vera Therapeutics
VERA
|
$14.8M |
Top Sells
| 1 |
CAVA Group
CAVA
|
$278M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$29.5M |
| 3 |
Viking Therapeutics
VKTX
|
$20.8M |
| 4 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$16.1M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$14.5M |
Sector Composition
| 1 | Consumer Discretionary | 56.42% |
| 2 | Healthcare | 42.2% |
| 3 | Technology | 0.99% |
| 4 | Financials | 0.15% |
| 5 | Consumer Staples | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Apogee Therapeutics
APGE
$2.27B
| – | – |
-152,500
| Closed | -$10.1M |
|
127
Advanced Micro Devices
AMD
$263B
| – | – |
-4,500
| Closed | -$812K |
|
|
ADAG
128
Adagene
ADAG
$103M
| – | – |
-1,020,000
| Closed | -$2.86M |
|
129
Apple
AAPL
$3.54T
| – | – |
-10,000
| Closed | -$1.71M |
|